On April 24th, 2024, the Chinese leading aesthetic medicine company IMEIK TECHNOLOGY DEVELOPMENT CO., LTD. (referred to as “IMEIK”) released its financial report for the first quarter of 2024.
The report indicates that in the first quarter of 2024, IMEIK achieved operating revenue of 808 million yuan, an increase of 28.24% year-on-year; net profit attributable to shareholders was 527 million yuan, up 27.38% year-on-year; and basic earnings per share were 2.45 yuan, up 28.27% year-on-year. Compared with the performance of the same period last year, which saw a 66% increase in revenue and a 64% increase in net profit, IMEIK’s performance growth in the first quarter of this year has declined.
The report also points out that in the first quarter, IMEIK’s operating costs increased by 48.56% year-on-year, mainly due to the increase in sales and associated costs; research and development expenses increased by 32.17% year-on-year, mainly due to an increase in research and development projects and related expenses during the reporting period.
Additionally, IMEIK disclosed an announcement regarding the completion of the implementation of the plan for the actual controller to increase holdings of the company’s shares and the results of the increase in holdings. According to the announcement, from October 26, 2023, to April 24, 2024, IMEIK’s actual controller and chairman, Jian Jun, accumulated 199,100 shares of the company through centralized bidding trading, accounting for 0.0925% of the total share capital after deducting the repurchased shares. The total amount of the increase in holdings was 62,537,800 yuan (excluding transaction costs), and the plan for this increase in holdings has been completed.
Furthermore, in the financial report 2023, IMEIK stated that in 2024, the company will continue to actively seek investment opportunities and closely monitor the research and development directions in leading global medical devices and biopharmaceuticals. Considering strategic alignment, synergies, market positioning, management team experience, research and development capabilities, and past operational and financial performance, the company will comprehensively evaluate potential business partners or investment targets.
Simultaneously, the company will actively explore opportunities in overseas markets, conduct in-depth research on different markets, and timely initiate product registration processes overseas to facilitate product globalization.
